Pharmaceuticals Protein Production Small Molecule 
Drug Target Review
NOVEMBER 1, 2023
The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.
The Pharma Data
OCTOBER 14, 2020
15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. SOURCE: Eloxx Pharmaceuticals, Inc. WALTHAM, Mass., Conference ID : 9467336. Source link.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dark Matter Blog
JULY 16, 2021
My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.
Codon
MARCH 20, 2023
Point-of-care peptide hormone production enabled by cell-free protein synthesis. Marine biofilm engineered to produce current in response to small molecules. Peroxisomal metabolic coupling improves fatty alcohol production from sole methanol in yeast. DeWinter MA. ACS Synthetic Biology. ACS Synthetic Biology.
Codon
MAY 29, 2025
While small-molecule drugs continue to play a critical role in modern medicine, we are witnessing a shift toward the increasing development of amino acid-based therapeutics. Toxic peptides and proteins, particularly from the venoms of animals, are predicted to be a major source of next-generation peptide and protein-based drugs.
Expert insights. Personalized for you.
96 
Let's personalize your content